Elixiron Immunotherapeutics (Cayman) Limited
TTPEX:7871126.00
TWD
-4.00
(-3.08%)
ISIN
KYG3106D1016
CUSIP
G3106D101
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Semi-annual Revenue
FRC
•
in mil. unless spec.Semi-annual Earnings Per Share
FRC
•
in mil. unless spec.Semi-annual Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Hung Kai Chen
- Full Time Employees
- 30
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Taipei Taiwan
- Website
- elixiron.com
- Similar Companies
- Business
- Elixiron Immunotherapeutics (Cayman) Limited is a clinical-stage biopharmaceutical company focused on the discovery and development of precision immunotherapies for neurodegenerative diseases, autoimmune disorders, and oncological conditions. The company utilizes proprietary drug discovery platforms integrating phage display technologies, single human B-cell cloning, multi-omics profiling, and artificial intelligence-driven analytics to develop targeted small molecules and biologic therapeutic candidates. Elixiron's research and clinical pipeline comprises Enrupatinib (EI-1071), an orally available, brain-penetrant small-molecule colony-stimulating factor 1 receptor (CSF-1R) inhibitor undergoing Phase II clinical development to modulate microglial neuroinflammation in Alzheimer's disease; Indemakitug (EI-001), a fully human anti-interferon-gamma (anti-IFN-gamma) monoclonal antibody in Phase II clinical trials for the treatment of vitiligo; EI-012, a targeted anti-CD36 monoclonal antibody candidate designed to reprogram tumor-associated macrophages for oncology applications; and EI-220, a preclinical mRNA-based immuno-oncology program. Founded in 2017, the company is incorporated and headquartered in Grand Cayman, Cayman Islands, and maintains principal executive, operational, and research and development facilities in Taipei, Taiwan, with clinical and regulatory operations in the United States. In recent developments, Elixiron listed its shares on the Taipei Exchange Emerging Stock Board under the ticker symbol 7871 in January 2026. The company reported positive interim Phase II clinical trial data for its lead neurodegenerative candidate Enrupatinib, supported by non-dilutive grant funding from the Alzheimer's Association Part the Cloud program, and advanced Indemakitug into Phase II clinical evaluation for vitiligo. Furthermore, Elixiron entered into an exclusive global out-licensing agreement with Pilatus Biosciences for its EI-012 immuno-oncology candidate, obtained Orphan Drug Designation from the United States Food and Drug Administration, and executed a strategic research collaboration with National Yang Ming Chiao Tung University to co-develop AI-driven therapeutic discovery pipelines.